作者
Jose M Rubio, Georgios Schoretsanitis, Majnu John, Jari Tiihonen, Heidi Taipale, Daniel Guinart, Anil K Malhotra, Christoph U Correll, John M Kane
发表日期
2020/9/1
期刊
The Lancet Psychiatry
卷号
7
期号
9
页码范围
749-761
出版商
Elsevier
简介
Background
Most individuals with schizophrenia-spectrum disorders have relapses, which increase the risk of morbidity and mortality. Because non-adherence to antipsychotic maintenance treatment could affect more than half of individuals with schizophrenia-spectrum disorders, psychosis relapse can often be confounded by unnoticed treatment interruption. Research of relapse during confirmed antipsychotic exposure has basic clinical and neurobiological implications, but data are scarce. We aimed to generate reliable estimates of incidence and predictors of relapse during assured antipsychotic treatment.
Methods
We did a systematic review and individual participant data (IPD) meta-analysis of clinical trials of long-acting injectable antipsychotics (LAIs) for psychosis relapse-prevention, following IPD-PRISMA guidelines. Datasets were identified by searching relevant repositories from inception to Aug 1, 2019 …
学术搜索中的文章
JM Rubio, G Schoretsanitis, M John, J Tiihonen… - The Lancet Psychiatry, 2020